Industry
Biotechnology
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Loading...
Open
42.15
Mkt cap
7.5B
Volume
1.9M
High
42.48
P/E Ratio
-26.59
52-wk high
70.13
Low
40.23
Div yield
N/A
52-wk low
38.60
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 2:15 pm
Portfolio Pulse from Benzinga Insights
October 16, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 10:58 am
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 10:12 am
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 11:34 am
Portfolio Pulse from Vandana Singh
September 30, 2024 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 10:37 am
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 8:33 pm
Portfolio Pulse from Benzinga Insights
September 27, 2024 | 2:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.